Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients

Journal of the American Society of Nephrology

Volumn 8, Issue 12, 1997, Pages 1889-1898

  Koch, Michael ^a   Kutkuhn, Bernd ^a   Trenkwalder, Evi ^b   Bach, Dieter ^a   Grabensee, Bernd ^a   Dieplinger, Hans ^b   Kronenberg, Florian ^b,c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c Inst of Med Biol and Hum Genet   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0031412660     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Held PJ, Port FK, Webb RL, Wolfe RA, Bloembergen WE, Turenne MN, Holzman E, Ojo AO, Young EW, Mauger EA: Excerpts from United States Renal Data System 1995 Annual Data Report. Am J Kidney Dis 26: S1-S186, 1995
2. Raine AEG, MacMahon SH, Selwood NH, Wing AJ, Brunner FP: Mortality from myocardial infarction in patients on renal replacement therapy in the U.K. [Abstract]. Nephrol Dial Transplant 6: 902, 1991
3. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP: Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 9: 1136-1142, 1994
4. Kronenberg F, Dieplinger H, König P, Utermann G: Lipoprotein metabolism in renal replacement therapy: A review. Isr J Med Sci 32: 371-389, 1996
5. Brunner FP, Selwood NH, on behalf of the EDTA Registration Committee: Profile of patients on RRT in Europe and death rates due to major causes of death groups. Kidney Int 42[Suppl 38]: S4-S15, 1992
6. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N: The uremic dyslipidemia: A cross-sectional and longitudinal study. Am J Kidney Dis 20: 324-335, 1992
7. Attman P-O, Alaupovic P: Lipid abnormalities in chronic renal insufficiency. Kidney Int 39[Suppl 31]: S16-S23, 1991
8. Goldberg AP, Harter HR, Patsch W, Schechtman KB, Province M, Weerts C, Kuisk I, McCrate MM, Schonfeld G: Racial differences in plasma high-density lipoproteins in patients receiving hemodialysis: A possible mechanism for accelerated atherosclerosis in white men. N Engl J Med 308: 1245-1252, 1983
9. Ritz E: Why are lipids not predictive of cardiovascular death in the dialysis patient? Miner Electrolyte Metab 22: 9-12, 1996
10. Utermann G: The mysteries of lipoprotein(a). Science 246: 904-910, 1989
11. Kronenberg F, Utermann G, Dieplinger H: Lipoprotein(a) in renal disease. Am J Kidney Dis 27: 1-25, 1996
12. Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6: 110-120, 1995
13. Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G: Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 36: 20-23, 1990
14. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D: Apolipoproteins (a), AI and B and parental history in men with early onset ischaemic heart disease. Lancet i: 1070-1073, 1988
15. Sunayama S, Daida H, Mokuno H, Miyano H, Yokoi H, Lee YJ, Sakurai H, Yamaguchi H: Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women > or = 55 years of age. Circulation 94: 1263-1268, 1996
16. Assmann G, Schulte H, Von Eckardstein A: Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77: 1179-1184, 1996
17. Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, Schober M, Moes N, König P, Utermann G, Dieplinger H: Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation. J Lipid Res 38: 1755-1763, 1997
18. Kronenberg F, Kathrein H, König P, Neyer U, Sturm W, Lhotta K, Gröchenig E, Utermann G, Dieplinger H: Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 14: 1405-1411, 1994
19. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson BO, Welin L, Tibblin G: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311: 501-505, 1984
20. Haaber AB, Eidemak I, Jensen T, Feldt-Rasmussen B, Strandgaard S: Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol 5: 1581-1584, 1995
21. Bostom AG, Shemin D, Lapane KL, Sutherland P, Nadeau MR, Wilson PWF, Yoburn D, Bausserman L, Tofler G, Jacques PF, Selhub J, Rosenberg IH: Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study. Atherosclerosis 125: 91-101, 1996
22. Bartens W, Nauck M, Schollmeyer P, Wanner C: Elevated lipoprotein(a) and fibrinogen serum levels increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 16: 27-33, 1996
23. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6: 121-125, 1995
24. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039-1057, 1979
25. Kronenberg F, Lobentanz E-M, König P, Utermann G, Dieplinger H: Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol and triglycerides. J Lipid Res 35: 1318-1328, 1994
26. Wieland H, Seidel D: A simple specific method for precipitation of low density lipoproteins. J Lipid Res 24: 904-909, 1983
27. Clauss A: Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 17: 237-246, 1957
28. Dieplinger H, Gruber G, Krasznai K, Reschauer S, Seidel C, Burns G, Müller H-J, Császár A, Vogel W, Robenek H, Utermann G: Kringle 4 of human apolipoprotein[a] shares a linear antigenic site with human catalase. J Lipid Res 36: 813-822, 1995
29. Kraft HG, Lingenhel A, Bader G, Kostner GM, Utermann G: The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: Proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis 125: 53-61, 1996
30. Budowle B, Giusti AM, Waye JS, Baechtel FS, Fourney RM, Adams DE, Presley LA, Deadman HA, Monson KL: Fixed-bin analysis for statistical evaluation of continuous distributions of allelic data from VNTR loci, for use in forensic comparisons. Am J Hum Genet 48: 841-855, 1991
31. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G: Apo(a) isoforms predict risk for coronary heart disease: A study in six populations. Arterioscler Thromb 12: 1214-1226, 1992
32. Mölgaard J, Klausen IC, Lassvik C, Faergeman O, Gerdes LU, Olsson AG: Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb 12: 895-901, 1992
33. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, König P: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 91: 397-401, 1993
34. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH: Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 90: 52-60, 1992
35. Kraft HG, Köchl S, Menzel HJ, Sandholzer C, Utermann G: The apolipoprotein(a) gene: A transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet 90: 220-230, 1992
36. Nunnally JC: Psychometric Theory, 2nd Ed., New York, McGraw-Hill, 1978.
37. Braun WE, Phillips DG, Vidt AC, Novick AC, Nakamoto S, Popowniak KL, Paganini E, Magnusson M, Pohl M, Steinmuller DR, Protiva D, Buszta C: Coronary artery disease in 100 diabetics with end-stage renal failure. Transplant Proc 16: 603-607, 1984
38. Rostand SG, Kirk KA, Rutsky EA: Dialysis-associated ischemic heart disease: Insights from coronary angiography. Kidney Int 25: 653-659, 1984
39. Koch M, Gradaus F, Schoebel F-C, Leschke M, Grabensee B: Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol Dial Transplant 12: 1187-1191, 1997
40. Koch M, Thomas B, Tschöpe W, Ritz E: Survival and predictors of death in dialysed diabetic patients. Diabetologia 36: 1113-1117, 1993
41. Wald NJ, Law M, Watt HC, Wu TS, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE: Apolipoproteins and ischaemic heart disease: Implications for screening. Lancet 343: 75-79, 1994
42. Attman P-O, Nyberg G, William-Olsson T, Knight-Gibson C, Alaupovic P: Dyslipoproteinemia in diabetic renal failure. Kidney Int 42: 1381-1389, 1992
43. Attman P-O, Alaupovic P: Lipid and apolipoprotein profiles of uremic dyslipoproteinemia: Relation to renal function and dialysis. Nephron 57: 401-410, 1991
44. Hahn R, Oette K, Mondorf H, Finke K, Sieberth HG: Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 48: 279-288, 1983
45. Rader DJ, Hoeg JM, Brewer HB Jr: Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 120: 1012-1025, 1994
46. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H: Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci 33: 495-543, 1996
47. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86: 475-482, 1992
48. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA: Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 10: 354-357, 1995
49. Wanner C, Bartens W, Walz G, Nauck M, Schollmeyer P: Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. Nephrol Dial Transplant 10: 75-81, 1995
50. Kraft HG, Lingenhel A, Köchl S, Hoppichler F, Kronenberg F, Abe A, Mühlberger V, Schönitzer D, Utermann G: Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 16: 713-719, 1996